Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20111434 | 0.86 | PTGS2 (0.40) | KDM1APTGS2FGFR2FGFR1FAAH | |
| SCHEMBL16852379 | 0.85 | FAAH (0.41) | KDM1APTGS2FGFR2FGFR1FAAH | |
| SCHEMBL20102414 | 0.84 | FGFR2 (0.39) | KDM1APTGS2FGFR2FGFR1PTGS1 | |
| SCHEMBL16855917 | 0.81 | FGFR2 (0.46) | KDM1APTGS2FGFR2FGFR1FAAH | |
| SCHEMBL16856038 | 0.77 | PTGS2 (0.47) | KDM1APTGS2PTGS1NAAAPRKCZ | |
| SCHEMBL20102530 | 0.77 | CTSL (0.34) | KDM1APTGS2FGFR2FGFR1PTGS1 | |
| SCHEMBL16852377 | 0.75 | NAAA (0.45) | KDM1APTGS2FGFR2FGFR1FAAH | |
| SCHEMBL16855842 | 0.75 | PTGS2 (0.43) | KDM1APTGS2FGFR2FGFR1FAAH | |
| SCHEMBL16855899 | 0.75 | L3MBTL1 (0.43) | KDM1APTGS2FGFR2FGFR1FAAH | |
| SCHEMBL16855895 | 0.75 | L3MBTL1 (0.43) | KDM1APTGS2FGFR2FGFR1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | KDM1A 1263/4885PTGS2 4062/4885FGFR2 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.